Ketanest-S (Esketamine Hydrochloride)

Esketamine, the active ingredient in Ketanest‑S, is a NMDA receptor antagonist presented as a solution for intramuscular and intravenous use. It provides rapid induction of anesthesia and analgesia for surgical patients. GNH USA supplies Ketanest‑S as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Esketamine, an NMDA receptor antagonist, is employed in anesthesia and procedural analgesia. - Induction of anesthesia: produces rapid dissociative anesthesia for surgical procedures. - Analgesia: provides effective pain relief during operative and diagnostic interventions.

Ketanest‑S may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness - Nausea - Vomiting - Increased blood pressure - Headache - Perceptual disturbances

Serious or Rare Side Effects: - Respiratory depression - Severe hypertension or cardiac arrhythmia - Emergence delirium or psychosis - Allergic reactions including anaphylaxis - Cardiac arrest - Prolonged sedation

When using Ketanest‑S, clinicians should observe specific safety measures. - Cardiovascular assessment: evaluate blood pressure and heart rate before administration. - Respiratory monitoring: continuously observe airway and breathing. - Contraindication in severe hypertension: avoid use in uncontrolled high blood pressure. - Psychiatric caution: use carefully in patients with a history of psychosis or severe mental illness. - Hepatic impairment: consider dose adjustment in significant liver disease. - Store at ambient temperature: keep in original container, protect from moisture and light, and do not freeze.

Esketamine may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other NMDA antagonists: additive dissociative effects.

Moderate Interactions (Monitor Closely): - Central nervous system depressants (e.g., benzodiazepines, opioids): enhanced sedation and respiratory depression. - Sympathomimetic agents (e.g., epinephrine): may exacerbate hypertension. - CYP2B6 inhibitors (e.g., ritonavir): potential increase in esketamine plasma levels.